PARVANEH SADEGHI Parvaneh is a laboratory technician in Research & Development in Novo NordiskDenmark

ComCase ‘15 Kickoff event

CBS, 27 November 2014

Mike Rulis & Charlotte Ersbøll

Novo TerapeutiskLaboratorium 1925

Merger of Novo Industriand Nordisk Gentofte 1989

Novo Nordisk 2000Nordisk Insulinlaboratorium1923

Novozymes 2000

The short version of our history

2Novo Nordisk - Corporate Presentation

14th largest pharmaceutical company in terms of sales (2013)

3

-

10,000

20,000

30,000

40,000

50,000

60,000

70,000

80,000

Billio

n U

S d

ollar

Sales

4

Our global presence

5Novo Nordisk - Corporate presentation

3 strategic R&D centresChina, Denmark, US

5 Strategic production sitesBrazil, China, Denmark, France, US

5 Regional headquartersChina, Japan, Europe, IO, North America

Global headquartersDenmark

75 affiliates

Novo Nordisk markets its products in 180 countries worldwide

Employees by region in 75 countries

We are more than 40,000 employees

6Novo Nordisk - Corporate presentation

1. Includes headquarter functions, R&D, production sites and sales office.

The objective of the Novo Nordisk Foundation is twofold:

• to provide a stable basis for the commercial and research activities conducted by the companies within the Novo Group

• to award significant amounts for scientific and humanitarian purposes

The Novo Nordisk Foundation approves the allocation of profits within Novo A/S.

Novo A/S is a holding company wholly-owned by the Novo Nordisk Foundation. Novo A/S manages the Foundation’s broad portfolio of financial assets through investments in the life science area.

Novo A/S is the majority shareholder in the listed companies Novo Nordisk A/S and Novozymes A/S.

Novo A/S holds 25.5% of the total share capital and 73% of the total number of votes. Other shareholders hold 74.5% of the total share capital and 27% of the total number of votes.

Novo Nordisk A/S is listed on NASDAQ OMX Copenhagen and New York Stock Exchange.

Ownership structure

7Novo Nordisk - Corporate Presentation

Novo Nordisk’s corporate strategy

8

Core capabilities

Expand leadership in

DIABETES

Pursue leadership in

HAEMOPHILIA

Establish presence in

OBESITY

Expand leadership in

GROWTH DISORDERS

Strategic priorities

Novo Nordisk Way

Engineering, formulating, developing and delivering protein-based treatments

Building and maintaining a leading position inemerging markets

Deep disease understanding

Efficient large-scale production of proteins

Planning and executing global launches of new products

The Novo Nordisk WayHow we want to achieve success

Our ambition is to strengthen our leadership in diabetes.

We aspire to change possibilities in haemophilia and other serious chronic conditions.

Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world.

9

The Triple Bottom Line

Introduction course 10

Patients

The diabetes pandemic

11

People waiting at a diabetes clinic in Tanzania

VL45 presentation

The global diabetes challenge

12

• Risk factors include:

• Urbanisation and rapid socio-economic transition – the ‘mismatch theory’

• Obesity

• Poor diet

• Physical inactivity

• Advancing age

• Family history in diabetes

• Ethnicity

• Gestational diabetes – risk for both mother and child

Why the explosive growth in type 2 diabetes?

13

14

The ‘Rule of Halves’ a story of missed opportunities

Actual rates of diagnosis, treatment, targets and outcomes vary in different countries

Diabetes – a European snapshot

15

1 in 3 people with diabetes do not know they have it

1 in 12 adults have diabetes

Diabetes costs 116 billion euros in direct health expenditures in Europe in 2014

Use Novo Nordisk’s diabetes products every day

16

24.3

Novo Nordisk Changing Diabetes

KOFI ANNAN and LISE KINGOSetting the agenda for change2013 IDLF, Turkey

17

18

Changing Diabetes®

Start with “why”

• “People don't buy what you do; they buy why you do it. And what you do simply proves what you believe.”

• “If you hire people just because they can do a job, they’ll work for your money. But if you hire people who believe what you believe, they’ll work for you with blood and sweat and tears.”

Simon Sinek, Author of “Start with why”

18

Changing Diabetes® is our promise to improve health and quality of life

Expand access to affordable care worldwide

Improve health outcomes for people with diabetes

• DAWN2

• Changing Diabetes®

barometer

• Healthcare professionals and patient training

• Action on Diabetes

• Changing Diabetes® 40by20 Patient Ambition

• LDC pricing policy

• Changing Diabetes® at the Base of the Pyramid

• Changing Diabetes® in Children

Prevent diabetes in future generations

• Changing Diabetes® in Pregnancy

• Changing Future Health

Drive awareness and public policy

• World Diabetes Day

• Changing Diabetes® Leadership Forums

• Changing Diabetes® Village

• Team Novo Nordisk

19

Changing Diabetes®

goes hand-in-hand with our business

Changing Diabetes® plans take their starting point in diabetes rule of halves with prioritised Changing Diabetes® actions where societal needs intersect with business opportunity

20

Presentation title Date 21

Novo NordiskAccess to Health

Strategy

Differential Pricing for LDCs

2011

World Partner Project

Oxford Health Alliance

Denmark and Russia

Support to UN Resolution

on Diabetes

20142001

Building on 10 years of Changing Diabetes®

New York

China

23

Changing Diabetes®

A Platform for strengthening stakeholder relations

UN adoption of Resolution on

diabetes

UN High-Level meeting on NCDs

2006 2007 2008 2009 2010 2011 2012 2013 2014

NCDs recognised in Rio+20 outcome

document

Novo Nordisk

World events

Europe Turkey Europe, Latin America & Pakistan

MENA & Africa ChinaRussiaUSA

First UN observed World Diabetes Day

WHO target on NCDs

2015

Changing Diabetes® Leadership ForumsThe journey

Post 2015: NCDs in UN Sustainable Development Goals

24

Leadership Forums put change on the agenda

Since 2007, we have convened 9 international and 52 national diabetes leadership forums.

13,000 high-level policy stakeholders and decision makers have engaged in the question of changing diabetes in 40 countries

Pursuing our goal to push diabetes to the top of the political and healthcare agenda around the world

25

Source: Novo Nordisk internal documents.

LARS REBIEN SØRENSEN, HRH CROWN PRINCE FREDERIK OF DENMARK, PRESIDENT BILL CLINTON, HH SHEIKH RASHID BIN HAMDAN AL MAKTOUM and MAKTOUM HASSAN ALI AL QASSAM. MENA Forum 2010 in Dubai, United Arab Emirates

17 countries

International Diabetes

Federation (IDF)

Steno Diabetes Center

International Alliance of Patient

Organizations (IAPO)

15,438 respondents

8,596 people with diabetes

2,057 family members

4,785 diabetes care professionals

Patient organisations and policy makers

1. Nicolucci A, et al. Diabet Med 2013;30:767–77; 2. Kovacs Burns K, et al. Diabet Med 2013;30:778–883. Holt RIG, et al. Diabet Med 2013;30:789–98

DAWN2™ - the world’s largest psychosocial studyWe start with the patient

26

The DAWN2™ study revealed that

• 19% of people with diabetes feel discriminated against because of their condition

• 37% of family members feel frustrated because they do not know how best to help their relative with diabetes

• 45% of people with diabetes experience diabetes-related distress

VERÓNICA RUBIO FRANCO WITH HER CHILDRENMexico

Verónica had gestational diabetesand now has type 2 diabetes

27

Team Novo Nordisk: racing to change diabetes

Team Novo Nordisk is a world-class sports programme for athletes with diabetes.

Their mission is to educate, empower and inspire people affected by diabetes. Team Novo Nordisk shows that it is possible for people with diabetes to live full lives and achieve ambitious personal goals.

Team Novo NordiskProfessional cycling team

28

The Fight against Urban Diabetes

29

Urban health: Emerging & untapped opportunity

Many cities face a triple threat:• Infectious diseases• Chronic, non-communicable diseases• Accidents, injuries, road accidents,

violence, and crime

Dr Margaret Chan, Director-General, WHO

One of my pet peeves is that obesity and diabetes – and their connection to community design – are virtually ignored by health scientists in the world of environmental advocacy, who remain almost exclusively focused on pollution

Dr Richard Jackson, MD, MPHDesigning Healthy Communities, Atlantic Cities

The rise of city mayors

“City leaders also govern the places where this century's most intractable problems play out – and where solutions are most likely to be found.”

“The White House Would Be a Step Down.No elective office can match the New York City mayoralty as a source of direct action to improve everyday life.”

“New York's next mayor needs to be ready to go global. “

Launched in Mexico City 25 March

32

In Mexico City we have the building blocks to tackle urban diabetes.”

The new frontline

• My argument today is that these two trends are related: global cities and global diabetes

• We believe that focusing on cities is the new frontline of the fight against diabetes

• What we need now is a wake-up call

• We need to make sure that urban diabetes is always on the agenda when people take decisions about managing cities

• We want to put this issue right to the top of the agenda of the global healthcare community

• We need a global fight against urban diabetes

- Lars Rebien Sørensen, Mexico City

34

Public-private partnerships

Global fight against urban diabetes

Urban diabetes is on the rise

Cities Changing Diabetes is our response

Activities

• Map the diabetes challenge in selected big cities across the world

• Share learning and best practices on how to break the Rule of Halves

• Implement action plans with local partners

México City28 March 2014

Copenhagen 22 August 2014

City partners

Houston3 November 2014

Tianjin13 November 2014

Shanghai14 November 2014

Cities Changing Diabetes aims to break the Rule of Halves and stop urban diabetes from ruining millions of lives

First-wave citiesNeed, business, opportunity, global spread

35

By 2025, 136 new cities are expected to enter the top 600, all of them from the developing world and overwhelmingly—100 new cities—from China.

McKinsey Global Institute

Mexico City

Houston

Copenhagen

Tianjin

36

The A

pis

bull lo

go is

a re

gis

tere

d tra

dem

ark

of N

ovo N

ord

isk A

/S38